Nearly Half of U.S. Families Struggle to Meet Basics in 2024
An independent analysis released this week shows nearly half u.s. families couldn't cover basic necessities in 2024, ...
Financial News — Page 403
EU Proposes Expanded Sanctions on Russia-Linked Crypto
EU officials weigh a broader crackdown on Russia-linked crypto platforms, with non-EU services facing tighter curbs a...
Danger Single-Bureau Blind Spot: Tri-Merge Solution
Lenders confront tight margins and a data gap that can hide risk. The danger single-bureau blind spot underscores why...
AI-Powered Real Estate Exam Prep Gains Traction in 2026
AI-driven prep tools are changing the way aspiring agents study for licensing, offering personalized plans and target...
The Responsible Framework Every Mortgage Lender Needs Now
As AI expands across mortgage processing and underwriting, lenders must adopt a responsible framework every mortgage ...
Visa’s Downplays Importance Stablecoin, Short-Term Focus
Visa’s CFO signaled that stablecoins and agentic commerce are not material to near-term growth, as the payments giant...
Billion Horse Race: Goldman Leads AI IPO Battle Ahead
Goldman Sachs and MORGAN STANLEY are jockeying for the lead left role in a pair of AI IPOs, a $7 billion opportunity ...
America’s Emergency Reserve About Hitting Reagan-Era Lows
The U.S. emergency oil stockpile is near its lowest level since 1983, with continued releases and global supply disru...
Retail Writes Ethereum, Making Recovery More Likely
Santiment flags extreme fear in Ethereum social sentiment as retail turns cautious. On-chain signals imply a countert...
Dogecoin Whales Buy the Dip as DOGE Hits 14-Month Low
Whales are stepping in to buy the dip as Dogecoin dips to a 14-month low. On-chain data shows a notable uptick in lar...
Claude Code Discovery Triggers Billion-Dollar Bug Today
A security researcher leveraged Claude-powered tooling to reveal a long-standing vulnerability in Zcash's Orchard cir...
Prediction: Pfizer Stock Could Double If Pipeline Delivers
Pfizer stock is navigating a pivot from COVID-era revenues to a broader drug portfolio. Analysts weigh the odds of a ...